Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Impact of Huntington's Disease on Mental Rotation Performance in Motor Pre-Symptomatic Individuals.

Nasr S, Rosas HD.

J Huntingtons Dis. 2019 Jul 9. doi: 10.3233/JHD-190348. [Epub ahead of print]

PMID:
31306138
2.

Electrocardiogram Abnormalities Suggest Aberrant Cardiac Conduction in Huntington's Disease.

Stephen CD, Hung J, Schifitto G, Hersch SM, Rosas HD.

Mov Disord Clin Pract. 2018 Apr 11;5(3):306-311. doi: 10.1002/mdc3.12596. eCollection 2018 May-Jun.

3.

Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease.

Rosas HD, Wilkens P, Salat DH, Mercaldo ND, Vangel M, Yendiki AY, Hersch SM.

Neuroimage Clin. 2018 Feb 19;20:236-242. doi: 10.1016/j.nicl.2018.01.029. eCollection 2018.

4.

Neuroinflammation in Huntington's Disease: New Insights with 11C-PBR28 PET/MRI.

Lois C, González I, Izquierdo-García D, Zürcher NR, Wilkens P, Loggia ML, Hooker JM, Rosas HD.

ACS Chem Neurosci. 2018 Nov 21;9(11):2563-2571. doi: 10.1021/acschemneuro.8b00072. Epub 2018 May 17.

PMID:
29719953
5.

The CREST-E study of creatine for Huntington disease: A randomized controlled trial.

Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD; Huntington Study Group CREST-E Investigators and Coordinators.

Neurology. 2017 Aug 8;89(6):594-601. doi: 10.1212/WNL.0000000000004209. Epub 2017 Jul 12.

6.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

7.

Differential associations between systemic markers of disease and cortical thickness in healthy middle-aged and older adults.

Coutinho AM, Coutu JP, Lindemer ER, Rosas HD, Rosen BR, Salat DH.

Neuroimage. 2017 Feb 1;146:19-27. doi: 10.1016/j.neuroimage.2016.11.021. Epub 2016 Nov 12.

8.
9.

Differential associations between systemic markers of disease and white matter tissue health in middle-aged and older adults.

Ryu CW, Coutu JP, Greka A, Rosas HD, Jahng GH, Rosen BR, Salat DH.

J Cereb Blood Flow Metab. 2017 Nov;37(11):3568-3579. doi: 10.1177/0271678X16653613. Epub 2016 Jul 21.

10.

Joint reconstruction of white-matter pathways from longitudinal diffusion MRI data with anatomical priors.

Yendiki A, Reuter M, Wilkens P, Rosas HD, Fischl B.

Neuroimage. 2016 Feb 15;127:277-286. doi: 10.1016/j.neuroimage.2015.12.003. Epub 2015 Dec 21.

11.

White Matter Changes are Associated with Ventricular Expansion in Aging, Mild Cognitive Impairment, and Alzheimer's Disease.

Coutu JP, Goldblatt A, Rosas HD, Salat DH; Alzheimer's Disease Neuroimaging Initiative (ADNI).

J Alzheimers Dis. 2016;49(2):329-42. doi: 10.3233/JAD-150306.

12.

A systems-level "misunderstanding": the plasma metabolome in Huntington's disease.

Rosas HD, Doros G, Bhasin S, Thomas B, Gevorkian S, Malarick K, Matson W, Hersch SM.

Ann Clin Transl Neurol. 2015 Jul;2(7):756-68. doi: 10.1002/acn3.214. Epub 2015 May 28.

13.

Tract-based analysis of white matter degeneration in Alzheimer's disease.

Lee SH, Coutu JP, Wilkens P, Yendiki A, Rosas HD, Salat DH; Alzheimer’s disease Neuroimaging Initiative (ADNI).

Neuroscience. 2015 Aug 20;301:79-89. doi: 10.1016/j.neuroscience.2015.05.049. Epub 2015 May 27.

14.

Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.

Narayanan KL, Chopra V, Rosas HD, Malarick K, Hersch S.

Mol Neurobiol. 2016 May;53(4):2132-40. doi: 10.1007/s12035-015-9147-9. Epub 2015 May 5.

15.

Effects of insulin resistance on white matter microstructure in middle-aged and older adults.

Ryu SY, Coutu JP, Rosas HD, Salat DH.

Neurology. 2014 May 27;82(21):1862-70. doi: 10.1212/WNL.0000000000000452. Epub 2014 Apr 25.

16.

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease.

Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, Triggs TD, Wilkens PJ, Matson W, Salat DH, Hersch SM.

Neurology. 2014 Mar 11;82(10):850-7. doi: 10.1212/WNL.0000000000000187. Epub 2014 Feb 7.

17.

Non-Gaussian water diffusion in aging white matter.

Coutu JP, Chen JJ, Rosas HD, Salat DH.

Neurobiol Aging. 2014 Jun;35(6):1412-21. doi: 10.1016/j.neurobiolaging.2013.12.001. Epub 2013 Dec 4.

18.

HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM; Huntington Study Group PHAROS Investigators.

Neurology. 2013 Sep 24;81(13):1134-40. doi: 10.1212/WNL.0b013e3182a55ede. Epub 2013 Aug 21.

19.

Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset.

Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME.

Neurogenetics. 2013 Nov;14(3-4):173-9. doi: 10.1007/s10048-013-0364-y. Epub 2013 May 4.

20.

The relationship between cortical blood flow and sub-cortical white-matter health across the adult age span.

Chen JJ, Rosas HD, Salat DH.

PLoS One. 2013;8(2):e56733. doi: 10.1371/journal.pone.0056733. Epub 2013 Feb 21.

21.

A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease.

Thomas B, Matson S, Chopra V, Sun L, Sharma S, Hersch S, Rosas HD, Scherzer C, Ferrante R, Matson W.

Anal Biochem. 2013 May 15;436(2):112-20. doi: 10.1016/j.ab.2013.01.035. Epub 2013 Feb 12.

22.

Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset.

Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME.

Hum Genet. 2012 Dec;131(12):1833-40. doi: 10.1007/s00439-012-1205-z. Epub 2012 Jul 25.

23.

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Landwehrmeyer GB; Registry Study of the European Huntington's Disease Network, Shoulson I; Huntington Study Group COHORT project, Myers RH, MacDonald ME, Gusella JF.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):404-8. Epub 2012 Jul 3.

24.

Within-subject template estimation for unbiased longitudinal image analysis.

Reuter M, Schmansky NJ, Rosas HD, Fischl B.

Neuroimage. 2012 Jul 16;61(4):1402-18. doi: 10.1016/j.neuroimage.2012.02.084. Epub 2012 Mar 10.

25.

Alterations in brain transition metals in Huntington disease: an evolving and intricate story.

Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, Kwong KK, Bush A, Fox J, Hersch SM.

Arch Neurol. 2012 Jul;69(7):887-93.

26.

Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region.

Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Griguoli A, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, MacDonald ME, Gusella JF.

Am J Hum Genet. 2012 Mar 9;90(3):434-44. doi: 10.1016/j.ajhg.2012.01.005. Epub 2012 Mar 1.

27.

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG.

Neurology. 2012 Mar 6;78(10):690-5. doi: 10.1212/WNL.0b013e318249f683. Epub 2012 Feb 8.

28.

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse.

Hu Y, Chopra V, Chopra R, Locascio JJ, Liao Z, Ding H, Zheng B, Matson WR, Ferrante RJ, Rosas HD, Hersch SM, Scherzer CR.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17141-6. doi: 10.1073/pnas.1104409108. Epub 2011 Oct 3.

29.

Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Chen JJ, Salat DH, Rosas HD.

Neuroimage. 2012 Jan 16;59(2):1043-51. doi: 10.1016/j.neuroimage.2011.08.112. Epub 2011 Sep 16.

30.

Biomarkers to Enable the Development of Neuroprotective Therapies for Huntington’s Disease.

Hersch SM, Rosas HD.

In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 11.

31.

A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.

Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch SM.

Mov Disord. 2011 Aug 1;26(9):1691-7. doi: 10.1002/mds.23762. Epub 2011 May 24.

32.

Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease.

Moscovitch-Lopatin M, Weiss A, Rosas HD, Ritch J, Doros G, Kegel KB, Difiglia M, Kuhn R, Bilbe G, Paganetti P, Hersch S.

PLoS Curr. 2010 Dec 29;2:RRN1205. doi: 10.1371/currents.RRN1205.

33.

Age-associated reductions in cerebral blood flow are independent from regional atrophy.

Chen JJ, Rosas HD, Salat DH.

Neuroimage. 2011 Mar 15;55(2):468-78. doi: 10.1016/j.neuroimage.2010.12.032. Epub 2010 Dec 16.

34.

Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count.

Weiss A, Grueninger S, Abramowski D, Giorgio FP, Lopatin MM, Rosas HD, Hersch S, Paganetti P.

Anal Biochem. 2011 Mar 15;410(2):304-6. doi: 10.1016/j.ab.2010.11.044. Epub 2010 Dec 4.

PMID:
21134349
35.

Tapping linked to function and structure in premanifest and symptomatic Huntington disease.

Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ, Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA, Landwehrmeyer GB, Langbehn DR, Stout JC, Tabrizi SJ, Reilmann R.

Neurology. 2010 Dec 14;75(24):2150-60. doi: 10.1212/WNL.0b013e3182020123. Epub 2010 Nov 10.

36.

Hippocampal degeneration is associated with temporal and limbic gray matter/white matter tissue contrast in Alzheimer's disease.

Salat DH, Chen JJ, van der Kouwe AJ, Greve DN, Fischl B, Rosas HD.

Neuroimage. 2011 Feb 1;54(3):1795-802. doi: 10.1016/j.neuroimage.2010.10.034. Epub 2010 Oct 18.

37.

Highly accurate inverse consistent registration: a robust approach.

Reuter M, Rosas HD, Fischl B.

Neuroimage. 2010 Dec;53(4):1181-96. doi: 10.1016/j.neuroimage.2010.07.020. Epub 2010 Jul 14.

38.

Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease.

Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K, Matson SA, Matson WR, Scherzer CR, Rosas HD, Hersch SM, Ferrante RJ.

Biochim Biophys Acta. 2010 Jul-Aug;1802(7-8):673-81. doi: 10.1016/j.bbadis.2010.05.001. Epub 2010 May 9.

39.

Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection".

Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, Fischl B, Pappu V, Onorato C, Cha JH, Salat DH, Hersch SM.

Neuroimage. 2010 Feb 15;49(4):2995-3004. doi: 10.1016/j.neuroimage.2009.10.015. Epub 2009 Oct 19.

40.

Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease.

Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, DiFiglia M, Fox J, Kegel K, Klein C, Grueninger S, Hersch S, Housman D, Régulier E, Rosas HD, Stefani M, Zeitlin S, Bilbe G, Paganetti P.

Anal Biochem. 2009 Dec 1;395(1):8-15. doi: 10.1016/j.ab.2009.08.001. Epub 2009 Aug 6.

PMID:
19664996
41.

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC; TRACK-HD investigators.

Lancet Neurol. 2009 Sep;8(9):791-801. doi: 10.1016/S1474-4422(09)70170-X. Epub 2009 Jul 29.

42.

Age-associated alterations in cortical gray and white matter signal intensity and gray to white matter contrast.

Salat DH, Lee SY, van der Kouwe AJ, Greve DN, Fischl B, Rosas HD.

Neuroimage. 2009 Oct 15;48(1):21-8. doi: 10.1016/j.neuroimage.2009.06.074. Epub 2009 Jul 4.

43.

Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM.

Ann N Y Acad Sci. 2008 Dec;1147:196-205. doi: 10.1196/annals.1427.034. Review.

44.

Linking SNPs to CAG repeat length in Huntington's disease patients.

Liu W, Kennington LA, Rosas HD, Hersch S, Cha JH, Zamore PD, Aronin N.

Nat Methods. 2008 Nov;5(11):951-3. doi: 10.1038/nmeth.1261. Epub 2008 Oct 19.

45.

Shorter telomeres may mark early risk of dementia: preliminary analysis of 62 participants from the nurses' health study.

Grodstein F, van Oijen M, Irizarry MC, Rosas HD, Hyman BT, Growdon JH, De Vivo I.

PLoS One. 2008 Feb 13;3(2):e1590. doi: 10.1371/journal.pone.0001590.

46.

Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications.

Brocklebank D, Gayán J, Andresen JM, Roberts SA, Young AB, Snodgrass SR, Penney JB, Ramos-Arroyo MA, Cha JJ, Rosas HD, Hersch SM, Feigin A, Cherny SS, Wexler NS, Housman DE, Cardon LR; International-Venezuela Collaborative Research Group.

Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):425-9. doi: 10.1002/ajmg.b.30826.

47.

The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals.

Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL.

Cereb Cortex. 2009 Mar;19(3):497-510. doi: 10.1093/cercor/bhn113. Epub 2008 Jul 16.

48.

White matter pathology isolates the hippocampal formation in Alzheimer's disease.

Salat DH, Tuch DS, van der Kouwe AJ, Greve DN, Pappu V, Lee SY, Hevelone ND, Zaleta AK, Growdon JH, Corkin S, Fischl B, Rosas HD.

Neurobiol Aging. 2010 Feb;31(2):244-56. doi: 10.1016/j.neurobiolaging.2008.03.013.

49.

Neuroprotection for Huntington's disease: ready, set, slow.

Hersch SM, Rosas HD.

Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003. Review.

50.

Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM.

Brain. 2008 Apr;131(Pt 4):1057-68. doi: 10.1093/brain/awn025. Epub 2008 Mar 12.

Supplemental Content

Loading ...
Support Center